UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

A DDL (C) (TIO) (A)	SU 111G D 1 MD	CID CM ALLA ADD IN HID MOD	4 mm 0 0 1 10 14 0 0 0 0 14 10 m 14 0	CONTRACTOR
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/528,630	06/29/2005	Bernd Bufe	BB-138	7026
23557 7590 . 10/18/2007 SALIWANCHIK LLOYD & SALIWANCHIK			EXAMINER	
A PROFESSIONAL ASSOCIATION PO BOX 142950			ULM, JOHN D	
	E, FL 32614-2950	•	ART UNIT	PAPER NUMBER
			MAIL DATE	DELIVERY MODE
			10/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
·	10/528,630	BUFE ET AL.		
Office Action Summary	Examiner	Art Unit		
·	John D. Ulm	1649		
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the o	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perions to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tired will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on 19 2a) This action is FINAL . 2b) The 3) Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, pro			
Disposition of Claims				
4) ⊠ Claim(s) 15-17 and 19 is/are pending in the 4a) Of the above claim(s) is/are withdrest signal is and 19 is/are rejected. 5) □ Claim(s) 15-17 and 19 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and	rawn from consideration.			
Application Papers	•			
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) and an applicant may not request that any objection to the Replacement drawing sheet(s) including the correct the correct of the correct	ccepted or b) objected to by the late drawing(s) be held in abeyance. Section is required if the drawing(s) is objection	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119		•		
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Di 5) Notice of Informal F 6) Other:	ate		

Application/Control Number: 10/528,630 Page 2

Art Unit: 1649

DETAILED ACTION

1) Claims 15 to 17 and 19 are pending in the instant application. Claims 15 to 17 and 19 have been amended and claims 1 to 5, 7, 9, 14 and 18 have been canceled as requested by Applicant in the correspondence filed 19 September of 2007.

- 2) The finality of the office action mailed 27 June of 2007 is withdrawn in view of the newly discovered Drayna et al. patent publication (US 20040248123).
- 3) Any objection or rejection of record that is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 4) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Specification

- 5) The instant specification does not comply with 37 C.F.R. § 1.77, which requires that:
 - (a) The elements of the application, if applicable, should appear in the following order:
 - (1) Utility Application Transmittal Form.
 - (2) Fee Transmittal Form.
 - (3) Title of the invention; or an introductory portion stating the name, citizenship, and residence of the applicant, and the title of the invention.
 - (4) Cross-reference to related applications.
 - (5) Statement regarding federally sponsored research or development.
 - (6) Reference to a "Microfiche appendix." (See § 1.96 (c)). The total number of microfiche and total number of frames should be specified.
 - (7) Background of the invention.
 - (8) Brief summary of the invention.

Art Unit: 1649

(9) Brief description of the several views of the drawing.

- (10) Detailed description of the invention.
- (11) Claim or claims.
- (12) Abstract of the Disclosure.
- (13) Drawings.
- (14) Executed oath or declaration.
- (15) Sequence Listing (See §§ 1.821 through 1.825).
- (b) The elements set forth in paragraphs (a)(3) through (a)(5), (a)(7) through (a)(12) and (a)(15) of this section should appear in upper case, without underlining or bold type, as section headings. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading. [43 FR 20464, May 11, 1978; 46 FR 2612, Jan. 12, 1981; paras. (h) and (i), 48 FR 2712, Jan. 20, 1983, effective Feb. 27, 1983; revised, 61 FR 42790, Aug. 19, 1996, effective Sept. 23, 1996].

Correction is required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 6) Claims 15 to 17 and 19 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by the Drayna et al. patent publication (US 20040248123). The amino acid sequence of the phenylthiocarbamide receptor described in Figure 1 of Drayna et al. is 99% identical to SEQ ID NO:1 of the instant application. The text beginning in paragraph 0113 of Drayna et al. expressly taught the identification of

Art Unit: 1649

antagonists, and the text in paragraph 0164 taught the administration of such antagonists.

Claim Rejections - 35 USC § 103

Page 4

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- To Claims 15, 17 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Drayna et al. patent publication (US 20040248123). In so far as these claims encompass a process that requires the administration of a test compound to a receptor protein prior to the administration of an agonist thereto, paragraph 0116 of Drayna et al. taught that "depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified". Whereas this text appears to anticipate these claims, even if it does not, an artisan would have found it *prima facie* obvious to have administered a test compound to a receptor protein before the administration of a known ligand thereto to facilitate the identification of compounds that block the binding of a known agonist to a receptor of interest.

Response to Arguments

8) Applicant's arguments with respect to claims 15 to 17 and 19 have been considered but are moot in view of the new ground(s) of rejection.

Application/Control Number: 10/528,630

Art Unit: 1649

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (571) 272-

0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.